| Name | Title | Contact Details |
|---|
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Bringing Together the Heart and Science of Medical Management Genex was founded in 1978 with the same directive it operates under today — helping injured workers return to their jobs in a safe and efficient manner through compassionate case management, thus reducing health care costs and disability expenses for our customers. Our medical and business professionals provide comprehensive care management and multicultural services from locations across the United States and Canada.
Elsevier Health Sciences is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kewanee Hospital has been serving our community since 1919. Our small, rural hospital has a core mission of "Improving the Health Care of Those We Serve." Located in west central Illinois, we have a long history of "friends and neighbors taking care of friends and neighbors."
Ra Pharma combines novel insights into complement and other innate immunity pathways with leadership in macrocycle technology to transform the lives of patients with life threatening disorders.